CEPI: Broadly protective Betacoronavirus (BPBC) vaccine
CEPI, the Coalition for Epidemic Preparedness Innovations launched a call for development of broadly protective vaccines against Betacoronavirus.
Subsidy: not specified
Total Budget: $200M (for both BPCoV2 and BPBC)
Deadline: 1 October 2021 (Application includes the submission of an Expression of Interest (EOI) and an invitation to submit a full proposal. An EOI may be submitted at any time and reviews will occur on a bi-monthly rolling basis.)
Project duration: 4 years
Consortium: Single applicant or a consortium are both eligible. This call is open, worldwide, to research and development organisations with expertise in vaccine development (at least one of the partners should have experience in human vaccine development and have a track record of bringing vaccine candidates through to human clinical trials in the past 5 years).
Scope: The main focus of this call is the research and development of novel immunogens for vaccine constructs able to elicit durable broadly protective responses.
Developed vaccine should be a broadly protective Betacoronavirus (BPBC) vaccine. Projects should aim to demonstrate clinical proof-of-concept.
The BPBC vaccine will involve the research and development of novel immunogens and platform technologies and should have a minimal Target Product Profile (TPP) that aims to protect against disease caused by the known Betacoronaviruses that already pose a significant epidemic or pandemic risk. An optimal TPP may additionally protect against novel Betacoronaviruses that pose a significant risk of spill over zoonoses and subsequent human transmission that results in new outbreaks.
Read more on the CEPI website
CEPI is an innovative global partnership between public, private, philanthropic, and civil society organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. Their mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.
CEPI recently also launched a call for development of broadly protective vaccines against SARS-CoV-2 variants (BPCoV2). Read more about the CEPI BPCoV2 grant.
To get free funding updates, including all new opportunities for research related to COVID-19, subscribe to Catalyze Alerts.